Structurally, its essentially a modified version of GHRH with a small molecular addition that increases its stability, allowing it to be used therapeutically
However, Eli Lilly also makes a medication called Zepbound (tirzepatide), which contains the same exact active ingredient as Mounjaro but is FDA-approved for weight loss instead
Conclusion: A Dual Path With Encouraging Direction GHK-Cu's unique dual-track regulatory path topical from Category 1 and injectable from Category 2, both heading to PCAC review before February 2027 reflects the complexity and nuance of the FDA's current approach to peptide regulation
Based on clinically available variables (BMI, waist circumference, OGTT/HOMA-IR, lipid profiles, NAFLD assessments, androgens, SHBG, and ultrasound markers), interpretable risk stratification models should be established rather than replacing clinical logic with black-box algorithms (173, 174)